Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

BACKGROUND: Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV) outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely that any intervention to mitigate this risk must address CV risk factors beyon...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zinman, Bernard, Inzucchi, Silvio E, Lachin, John M, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Kempthorne-Rawson, Joan, Newman, Jennifer, Johansen, Odd Erik, Woerle, Hans-Juergen, Broedl, Uli C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2014
Gaiak:
Study Protocol
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4072621/
https://ncbi.nlm.nih.gov/pubmed/24943000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2840-13-102
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak